Clinical Immunotherapy Program Archives

Speakers of the inaugural Shea Symposium

The inaugural symposium featured talks on adoptive cellular therapy for lymphoid malignancies and novel approaches for the treatment of acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.

Illustrated graphic of a scope target on a cell at a micro level.

CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.

Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.

As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.

The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.

Tag: Clinical Immunotherapy Program

Thomas C. Shea Clinical Cancer Symposium brings together national leaders in blood cancers

Questions and answers about CAR-T therapy

Parents, supporters create new fund for CAR-T therapy

Precision Oncology News: Carisma Therapeutics Begins Study of CAR Macrophage Therapy for HER2-Overexpressing Solid Tumors

Engineered safety switch curbs severe side effects of CAR-T immunotherapy

European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy

Pharmacy Times: Study Suggests Way to Boost Immunotherapy Against Breast Cancer, Other Solid Tumors

Fierce Biotech: Research Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors

Drug Target Review: Activating STING enhances CAR T-cell activity in solid tumours, shows study

United Press International: Study: Modified immunotherapy may work in advanced breast cancer